On the biomedical promise of cell penetrating peptides: Limits versus prospects

Journal of Pharmaceutical Sciences

Volumn 97, Issue 1, 2008, Pages 144-162

  Foerg, Christina ^a   Merkle, Hans P ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Cell penetrating peptides; Cellular differentiation; Cellular translocation; Drug delivery; Endocytosis; Inflammatory model; Review; Rho GTPases; Tight junctions

Indexed keywords

ANTENNAPEDIA PROTEIN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; CAVEOLIN 1; CELL PENETRATING PEPTIDE; CHLOROQUINE; CONTRAST MEDIUM; CYCLOSPORIN A; DOXORUBICIN; FIBRONECTIN; GUANOSINE TRIPHOSPHATASE; LIPOSOME; PENETRATIN; PEPTIDE NUCLEIC ACID; PROTAMINE; PROTEIN BCL XL; PROTEIN KFF3K; PROTEIN P53; PROTEIN PVEC; PROTEIN TP10; PROTEIN VP22; RHO FACTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; STREPTAVIDIN; TRANSACTIVATOR PROTEIN; TRANSACTIVATOR PROTEIN TC 99M; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; CANCER CELL CULTURE; CANDIDA ALBICANS; CELL DIFFERENTIATION; CELL MEMBRANE; CELL MIGRATION; CELL TRANSPORT; CONFOCAL LASER MICROSCOPY; CYTOSOL; DROSOPHILA; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG TARGETING; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; ENZYME STABILITY; EXTRACELLULAR MATRIX; GENE TRANSLOCATION; GOLGI COMPLEX; HEMATOCRIT; HUMAN; MAMMAL CELL; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; PSEUDOMONAS AERUGINOSA; REGULATORY MECHANISM; REVIEW; SACCHAROMYCES CEREVISIAE;

EID: 38349174536     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21117     Document Type: Article

References (168)

1. Juliano RL, Alahari S, Yoo H, Kole R, Cho M. 1999. Antisense pharmacodynamics: Critical issues in the transport and delivery of antisense oligonucleotides. Pharm Res 16:494-502.
2. Gewirtz AM, Sokol DL, Ratajczak MZ. 1998. Nucleic acid therapeutics: State of the art and future prospects. Blood 92:712-736.
3. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. 1999. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285:1569-1572.
4. Derossi D, Joliot AH, Chassaing G, Prochiantz A. 1994. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269:10444-10450.
5. Vives E, Brodin P, Lebleu B. 1997. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272:16010-16017.
6. Pooga M, Hallbrink M, Zorko M, Langel U. 1998. Cell penetration by transportan. FASEB J 12:67-77.
7. Schwarze SR, Dowdy SF. 2000. In vivo protein transduction: Intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 21:45-48.
8. Dietz GP, Bdeltahr M. 2004. Delivery of bioactive molecules into the cell: The Trojan horse approach. Mol Cell Neurosci 27:85-131.
9. Magzoub M, Graslund A. 2004. Cell-penetrating peptides: Small from inception to application. Q Rev Biophys 37:147-195.
10. Chaloin L, Vidal P, Lory P, Mery J, Lautredou N, Divita G, Heitz F. 1998. Design of carrier peptide-oligonucleotide conjugates with rapid membrane translocation and nuclear localization properties. Biochem Biophys Res Commun 243:601-608.
11. Park CB, Kim HS, Kim SC. 1998. Mechanism of action of the antimicrobial peptide buforin II: Buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 244:253-257.
12. Frank RW, Gennaro R, Schneider K, Przybylski M, Romeo D. 1990. Amino acid sequences of two proline-rich bactenecins. Antimicrobial peptides of bovine neutrophils. J Biol Chem 265:18871-18874.
13. Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J. 2000. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 57:679-686.
14. Skerlavaj B, Romeo D, Gennaro R. 1990. Rapid membrane permeabilization and inhibition of vital functions of gram-negative bacteria by bactenecins. Infect Immun 58:3724-3730.
15. Sokolov Y, Mirzabekov T, Martin DW, Lehrer RI, Kagan BL. 1999. Membrane channel formation by antimicrobial protegrins. Biochim Biophys Acta 1420:23-29.
16. Elmquist A, Langel U. 2003. In vitro uptake and stability study of pVEC and its all-D analog. Biol Chem 384:387-393.
17. Elmquist A, Lindgren M, Bartfai T, Langel U. 2001. VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions. Exp Cell Res 269:237-244.
18. Cashman SM, Sadowski SL, Morris DJ, Frederick J, Kumar-Singh R. 2002. Intercellular trafficking of adenovirus-delivered HSV VP22 from the retinal pigment epithelium to the photoreceptors-implications for gene therapy. Mol Ther 6:813-823.
19. Elliott G, O'Hare P. 1999. Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther 6:149-151.
20. Normand N, van Leeuwen H, O'Hare P. 2001. Particle formation by a conserved domain of the herpes simplex virus protein VP22 facilitating protein and nucleic acid delivery. J Biol Chem 276:15042-15050.
21. Krauss U, Muller M, Stahl M, Beck-Sickinger AG. 2004. In vitro gene delivery by a novel human calcitonin (hCT)-derived carrier peptide. Bioorg Med Chem Lett 14:51-54.
22. Machova Z, Muhle C, Krauss U, Trehin R, Koch A, Merkle HP, Beck-Sickinger AG. 2002. Cellular internalization of enhanced green fluorescent protein ligated to a human calcitonin-based carrier peptide. Chem Biochem 3:672-677.
23. Trehin R, Krauss U, Muff R, Meinecke M, Beck-Sickinger AG, Merkle HP. 2004. Cellular internalization of human calcitonin derived peptides in MDCK monolayers: A comparative study with Tat(47-57) and penetratin (43-58). Pharm Res 21:33-42.
24. Schmidt MC, Rothen-Rutishauser B, Rist B, Beck-Sickinger A, Wunderli-Allenspach H, Rubas W, Sadee W, Merkle HP. 1998. Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane. Biochemistry 37:16582-16590.
25. Crespo L, Sanclimens G, Montaner B, Perez-Tomas R, Royo M, Pons M, Albericio F, Giralt E. 2002. Peptide dendrimers based on polyproline helices. J Am Chem Soc 124:8876-8883.
26. Fernandez-Carneado J, Kogan MJ, Castel S, Giralt E. 2004. Potential peptide carriers: Amphipathic proline-rich peptides derived from the N-terminal domain of gamma-zein. Angew Chem Int Ed Engl 43:1811-1814.
27. Fernandez-Carneado J, Kogan MJ, Pujals S, Giralt E. 2004. Amphipathic peptides and drug delivery. Biopolymers 76:196-203.
28. Borsello T, Clarke PG, Hirt L, Vercelli A, Repici M, Schorderet DF, Bogousslavsky J, Bonny C. 2003. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 9:1180-1186.
29. Giorello L, Clerico L, Pescarolo MP, Vikhanskaya F, Salmona M, Colella G, Bruno S, Mancuso T, Bagnasco L, Russo P, Parodi S. 1998. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res 58:3654-3659.
30. Yuan J, Kramer A, Eckerdt F, Kaufmann M, Strebhardt K. 2002. Efficient internalization of the polo-box of polo-like kinase 1 fused to an Antennapedia peptide results in inhibition of cancer cell proliferation. Cancer Res 62:4186-4190.
31. Ezhevsky SA, Ho A, Becker-Hapak M, Davis PK, Dowdy SF. 2001. Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol Cell Biol 21:4773-484.
32. Harada H, Hiraoka M, Kizaka-Kondoh S. 2002. Antitumor effect of TAT-oxygen- dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 62:2013-2018.
33. Klekotka PA, Santoro SA, Ho A, Dowdy SF, Zutter MM. 2001. Mammary epithelial cell-cycle progression via the alpha(2)beta(1) integrin: Unique and synergistic roles of the alpha(2) cytoplasmic domain. Am J Pathol 159:983-992.
34. Lissy NA, Davis PK, Irwin M, Kaelin WG, Dowdy SF. 2000. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature 407:642-645.
35. Astriab-Fisher A, Sergueev DS, Fisher M, Shaw BR, Juliano RL. 2000. Antisense inhibition of Pglycoprotein expression using peptide-oligonucleotide conjugates. Biochem Pharmacol 60:83-90.
36. Cutrona G, Carpaneto EM, Ulivi M, Roncella S, Landt O, Ferrarini M, Boffa LC. 2000. Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nat Biotechnol 18:300-303.
37. Moulton HM, Hase MC, Smith KM, Iversen PL. 2003. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev 13:31-43.
38. Pooga M, Soomets U, Hallbrink M, Valkna A, Saar K, Rezaei K, Kahl U, Hao JX, Xu XJ, Wiesenfeld-Hallin Z, Hokfelt T, Bartfai T, Langel U. 1998. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol 16:857-861.
39. Simeoni F, Morris MC, Heitz F, Divita G. 2003. Insight into the mechanism of the peptide-based gene delivery system MPG: Implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 31:2717-2724.
40. Simeoni F, Morris MC, Heitz F, Divita G. 2005. Peptide-based strategy for siRNA delivery into mammalian cells. Methods Mol Biol 309:251-260.
41. Branden LJ, Mohamed AJ, Smith CI. 1999. A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat Biotechnol 17:784-787.
42. Ignatovich IA, Dizhe EB, Pavlotskaya AV, Akifiev BN, Burov SV, Orlov SV, Perevozchikov AP. 2003. Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. J Biol Chem 278:42625-42636.
43. Rudolph C, Plank C, Lausier J, Schillinger U, Muller RH, Rosenecker J. 2003. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J Biol Chem 278:11411-11418.
44. Tung CH, Mueller S, Weissleder R. 2002. Novel branching membrane transnational peptide as gene delivery vector. Bioorg Med Chem 10:3609-3614.
45. Krauss U, Kratz F, Beck-Sickinger AG. 2003. Novel daunorubicin-carrier peptide conjugates derived from human calcitonin segments. J Mol Recognit 16:280-287.
46. Mazel M, Clair P, Rousselle C, Vidal P, Scherrmann JM, Mathieu D, Temsamam J. 2001. Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs 12:107-116.
47. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. 2001. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA 98:8786-8791.
48. de la Fuente JM, Berry CC. 2005. Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjug Chem 16:1176-1180.
49. Koch AM, Reynolds F, Kircher MF, Merkle HP, Weissleder R, Josephson L. 2003. Uptake and metabolism of a dual fluorochrome Tat-nanoparticle in HeLa cells. Bioconjug Chem 14:1115-1121.
50. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, Weissleder R. 2000. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 18:410-414.
51. Jarver P, Langel U. 2004. The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov Today 9:395-402.
52. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC. 1993. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 67:277-287.
53. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J. 1994. Tat- mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 91:664-668.
54. Frankel AD, Pabo CO. 1988. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55:1189-1193.
55. Schwarze SR, Hruska KA, Dowdy SF. 2000. Protein transduction: Unrestricted delivery into all cells? Trends Cell Biol 10:290-295.
56. Futaki S. 2002. Arginine-rich peptides: Potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int J Pharm 245:1-7.
57. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y. 2001. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276:5836-5840.
58. Mitchell DJ, Kim DT, Steinman L, Fathman CG, Rothbard JB. 2000. Polyarginine enters cells more efficiently than other polycationic homopolymers. J Pept Res 56:318-325.
59. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. 2000. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc Natl Acad Sci USA 97:13003-13008.
60. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, Wender PA, Khavari PA. 2000. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 6:1253-1257.
61. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. 1996. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 271:18188-18193.
62. Drin G, Mazel M, Clair P, Mathieu D, Kaczorek M, Temsamani J. 2001. Physico-chemical requirements for cellular uptake of pAntp peptide. Role of lipid-binding affinity. Eur J Biochem 268:1304-1314.
63. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. 1991. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 88:1864-1868.
64. Karlsson O, Thor S, Norberg T, Ohlsson H, Edlund T. 1990. Insulin gene enhancer binding protein Isl1 is a member of a novel class of proteins containing both a homeo- and a Cys-His domain. Nature 344:879-882.
65. Kilk K, Magzoub M, Pooga M, Eriksson LE, Langel U, Graslund A. 2001. Cellular internalization of a cargo complex with a novel peptide derived from the third helix of the islet-1 homeodomain. Comparison with the penetratin peptide. Bioconjug Chem 12:911-916.
66. Pugliese L, Coda A, Malcovati M, Bolognesi M. 1993. Three-dimensional structure of the tetragonal crystal form of egg-white avidin in its functional complex with biotin at 2.7 A resolution. J Mol Biol 231:698-710.
67. Pooga M, Kut C, Kihlmark M, Hallbrink M, Fernaeus S, Raid R, Land T, Hallberg E, Bartfai T, Langel U. 2001. Cellular translocation of proteins by transportan. FASEB J 15:1451-1453.
68. Pooga M, Jureus A, Razaei K, Hasanvan H, Saar K, Kask K, Kjellen P, Land T, Halonen J, Maeorg U, Uri A, Solyom S, Bartfai T, Langel U. 1998. Novel galanin receptor ligands. J Pept Res 51:65-74.
69. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G. 1997. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 25:2730-2736.
70. Vidal P, Chaloin L, Mery J, Lamb N, Lautredou N, Bennes R, Heitz F. 1996. Solid-phase synthesis and cellular localization of a C- and/or N-terminal labelled peptide. J Pept Sci 2:125-133.
71. Deshayes S, Gerbal-Chaloin S, Morris MC, Aldrian-Herrada G, Charnet P, Divita G, Heitz F. 2004. On the mechanism of non-endosomial peptide-mediated cellular delivery of nucleic acids. Biochim Biophys Acta 1667:141-147.
72. Deshayes S, Heitz A, Morris MC, Charnet P, Divita G, Heitz F. 2004. Insight into the mechanism of internalization of the cell-penetrating carrier peptide Pep-1 through conformational analysis. Biochemistry 43:1449-1457.
73. Morris MC, Depollier J, Mery J, Heitz F, Divita G. 2001. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19:1173-1176.
74. Takeshima K, Chikushi A, Lee KK, Yonehara S, Matsuzaki K. 2003. Translocation of analogues of the antimicrobial peptides magainin and buforin across human cell membranes. J Biol Chem 278:1310-1315.
75. Sadler K, Eom KD, Yang JL, Dimitrova Y, Tam JP. 2002. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry 41:14150-14157.
76. Rousselle C, Smirnova M, Clair P, Lefauconnier JM, Chavanieu A, Calas B, Scherrmann JM, Temsamani J. 2001. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: Saturation kinetics and specificity. J Pharmacol Exp Ther 296:124-131.
77. Herbig ME, Fromm U, Leuenberger J, Krauss U, Beck-Sickinger AG, Merkle HP. 2005. Bilayer interaction and localization of cell penetrating peptides with model membranes: A comparative study of a human calcitonin (hCT)-derived peptide with pVEC and pAntp (43-58). Biochim Biophys Acta 1712:197-211.
78. Silverman SL. 1997. Calcitonin. Am J Med Sci 313:13-16.
79. Trehin R, Krauss U, Beck-Sickinger AG, Merkle HP, Nielsen HM. 2004. Cellular uptake but low permeation of human calcitonin-derived cell penetrating peptides and Tat(47-57) through well-differentiated epithelial models. Pharm Res 21:1248-1256.
80. Foerg C, Ziegler U, Fernandez-Carneado J, Giralt E, Rennert R, Beck-Sickinger AG, Merkle HP. 2005. Decoding the entry of two novel cell-penetrating peptides in HeLa cells: Lipid raft-mediated endocytosis and endosomal escape. Biochemistry 44:72-81.
81. Reynolds F, Weissleder R, Josephson L. 2005. Protamine as an efficient membrane-translocating Peptide. Bioconjug Chem 16:1240-1245.
82. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV, Lebleu B. 2003. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 278:585-590.
83. Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. 2003. Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 278:31192-31201.
84. Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K. 2003. Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem 278:35109-35114.
85. Zaro JL, Rajapaksa TE, Okamoto CT, Shen WC. 2006. Membrane transduction of oligoarginine in HeLa cells is not mediated by macropinocytosis. Mol Pharm 3:181-186.
86. Zaro JL, Shen WC. 2005. Cytosolic delivery of a p16-peptide oligoarginine conjugate for inhibiting proliferation of MCF7 cells. J Control Release 108:409-417.
87. Schmid SL. 1997. Clathrin-coated vesicle formation and protein sorting: An integrated process. Annu Rev Biochem 66:511-548.
88. Vendeville A, Rayne F, Bonhoure A, Bettache N, Montcourrier P, Beaumelle B. 2004. HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses. Mol Biol Cell 15:2347-2360.
89. Nichols BJ, Kenworthy AK, Polishchuk RS, Lodge R, Roberts TH, Hirschberg K, Phair RD, Lippincott-Schwartz J. 2001. Rapid cycling of lipid raft markers between the cell surface and Golgi complex. J Cell Biol 153:529-541.
90. Pelkmans L, Kartenbeck J, Helenius A. 2001. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol 3:473-483.
91. Puri V, Watanabe R, Singh RD, Dominguez M, Brown JC, Wheatley CL, Marks DL, Pagano RE. 2001. Clathrin-dependent and -independent internalization of plasma membrane sphingolipids initiates two Golgi targeting pathways. J Cell Biol 154:535-547.
92. Wadia JS, Dowdy SF. 2005. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 57:579-596.
93. Wadia JS, Stan RV, Dowdy SF. 2004. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10:310-315.
94. Vives E. 2003. Cellular uptake [correction of utake] of the Tat peptide: An endocytosis mechanism following ionic interactions. J Mol Recognit 16:265-271.
95. Fischer R, Kohler K, Fotin-Mleczek M, Brock R. 2004. A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J Biol Chem 279:12625-12635.
96. Lord JM, Roberts LM. 1998. Toxin entry: Retrograde transport through the secretory pathway. J Cell Biol 140:733-736.
97. Sandvig K, van Deurs B. 2000. Entry of ricin and Shiga toxin into cells: Molecular mechanisms and medical perspectives. EMBO J 19:5943-5950.
98. Sandvig K, van Deurs B. 2002. Membrane traffic exploited by protein toxins. Annu Rev Cell Dev Biol 18:1-24.
99. Al-Taei S, Penning NA, Simpson JC, Futaki S, Takeuchi T, Nakase I, Jones AT. 2006. Intracellular traffic and fate of protein transduction domains HIV-1 TAT peptide and octaarginine. Implications for their utilization as drug delivery vectors. Bioconjug Chem 17:90-100.
100. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, Sessa WC. 2000. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 6:1362-1367.
101. Barka T, Gresik EW, van Der Noen H. 2000. Transduction of TAT-HA-beta-galactosidase fusion protein into salivary gland-derived cells and organ cultures of the developing gland, and into rat submandibular gland in vivo. J Histochem Cytochem 48:1453-1460.
102. Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, Lu A, Ran R, Graham SH, Chen J. 2002. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 22:5423-5431.
103. Koppelhus U, Awasthi SK, Zachar V, Holst HU, Ebbesen P, Nielsen PE. 2002. Cell-dependent differential cellular uptake of PNA, peptides, and PNA-peptide conjugates. Antisense Nucleic Acid Drug Dev 12:51-63.
104. Kramer SD, Wunderli-Allenspach H. 2003. No entry for TAT(44-57) into liposomes and intact MDCK cells: Novel approach to study membrane permeation of cell-penetrating peptides. Biochim Biophys Acta 1609:161-169.
105. Violini S, Sharma V, Prior JL, Dyszlewski M, Piwnica-Worms D. 2002. Evidence for a plasma membrane-mediated permeability barrier to Tat basic domain in well-differentiated epithelial cells: Lack of correlation with heparan sulfate. Biochemistry 41:12652-12661.
106. Falnes PO, Wesche J, Olsnes S. 2001. Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment. Biochemistry 40:4349-4358.
107. Zhang X, Wan L, Pooyan S, Su Y, Gardner CR, Leibowitz MJ, Stein S, Sinko PJ. 2004. Quantitative assessment of the cell penetrating properties of RI-Tat-9: Evidence for a cell type-specific barrier at the plasma membrane of epithelial cells. Mol Pharm 1:145-155.
108. Caron NJ, Torrente Y, Camirand G, Bujold M, Chapdelaine P, Leriche K, Bresolin N, Tremblay JP. 2001. Intracellular delivery of a Tat-eGFP fusion protein into muscle cells. Mol Ther 3:310-318.
109. Niesner U, Halin C, Lozzi L, Gunthert M, Neri P, Wunderli-Allenspach H, Zardi L, Neri D. 2002. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem 13:729-736.
110. Leifert JA, Harkins S, Whitton JL. 2002. Fulllength proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. Gene Ther 9:1422-1428.
111. Xia H, Mao Q, Davidson BL. 2001. The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol 19:640-644.
112. Lee HJ, Pardridge WM. 2001. Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo. Bioconjug Chem 12:995-999.
113. Tseng YL, Liu JJ, Hong RL. 2002. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: A kinetic and efficacy study. Mol Pharmacol 62:864-872.
114. Polyakov V, Sharma V, Dahlheimer JL, Pica CM, Luker GD, Piwnica-Worms D. 2000. Novel, Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human cells for imaging and radiotherapy. Bioconjug Chem 11:762-771.
115. Lindgren ME, Hallbrink MM, Elmquist AM, Langel U. 2004. Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochem J 377:69-76.
116. Soomets U, Lindgren M, Gallet X, Hallbrink M, Elmquist A, Balaspiri L, Zorko M, Pooga M, Brasseur R, Langel U. 2000. Deletion analogues of transportan. Biochim Biophys Acta 1467:165-176.
117. Trehin R, Nielsen HM, Jahnke HG, Krauss U, Beck-Sickinger AG, Merkle HP. 2004. Metabolic cleavage of cell penetrating peptides in contact with epithelial models: Human Calcitonin (hCT) derived peptides, Tat(47-57) and penetratin (43-58). Biochem J 382:945-956.
118. Foerg C, Weller KM, Rechsteiner H, Nielsen HM, Fernández-Carneado J, Brunisholz R, Giralt E, Merkle HP. Metabolic cleavage and translocation efficiency of selected cell penetrating peptides a comparative study with epithelial cell cultures (Manuscript submitted).
119. Holm T, Netzereab S, Hansen M, Langel U, Hallbrink M. 2005. Uptake of cell-penetrating peptides in yeasts. FEBS Lett 579:5217-5222.
120. Foerg C, Ziegler U, Fernandez-Carneado J, Giralt E, Merkle HP. 2007. Differentiation restricted endocytosis of cell penetrating peptides in MDCK cells relates with activities of Rho-GTPases. Pharm Res 24:628-642.
121. Cereijido M, Robbins E, Sabatini DD, Stefani E. 1984. Cell-to-cell communication in monolayers of epithelioid cells (MDCK) as a function of the age of the monolayer. J Membr Biol 81:41-48.
122. Cereyido M, Valdes J, Shoshani L, Contreras RG. 1998. Role of tight junctions in establishing and maintaining cell polarity. Annu Rev Physiol 60:161-177.
123. Harhaj NS, Antonetti DA. 2004. Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol 36:1206-1237.
124. van Meer G, Gumbiner B, Simons K. 1986. The tight junction does not allow lipid molecules to diffuse from one epithelial cell to the next. Nature 322:639-641.
125. van Meer G, Simons K. 1986. The function of tight junctions in maintaining differences in lipid composition between the apical and the basolateral cell surface domains of MDCK cells. EMBO J 5:1455-1464.
126. Ferrari A, Pellegrini V, Arcangeli C, Fittipaldi A, Giacca M, Beltram F. 2003. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. MoI Ther 8:284-294.
127. Hallbrink M, Floren A, Elmquist A, Pooga M, Bartfai T, Langel U. 2001. Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta 1515:101-109.
128. Tyagi M, Rusnati M, Presta M, Giacca M. 2001. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 276: 3254-3261.
129. Ellis S, Mellor H. 2000. Regulation of endocytic traffic by rho family GTPases. Trends Cell Biol 10:85-88.
130. Etienne-Manneville S, Hall A. 2002. Rho GTPases in cell biology. Nature 420:629-635.
131. Van Aelst L, D'Souza-Schorey C. 1997. Rho GTPases and signaling networks. Genes Dev 11:2295-2322.
132. Bourne HR. 1993. GTPases. A turn-on and a surprise. Nature 366:628-629.
133. Hall A. 1998. Rho GTPases and the actin cytoskeleton. Science 279:509-514.
134. Qualmann B, Mellor H. 2003. Regulation of endocytic traffic by Rho GTPases. Biochem J 371:233-241.
135. Rivero F, Somesh BP. 2002. Signal transduction pathways regulated by Rho GTPases in Dictyostelium. J Muscle Res Cell Motil 23:737-749.
136. Symons M, Rusk N. 2003. Control of vesicular trafficking by Rho GTPases. Curr Biol 13:R409-R418.
137. Fukata M, Nakagawa M, Kaibuchi K. 2003. Roles of Rho-family GTPases in cell polarisation and directional migration. Curr Opin Cell Biol 15:590-597.
138. Nobes CD, Hall A. 1995. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81:53-62.
139. Qualmann B, Kessels MM, Kelly RB. 2000. Molecular links between endocytosis and the actin cytoskeleton. J Cell Biol 150:F111-F116.
140. Chimini G, Chavrier P. 2000. Function of Rho family proteins in actin dynamics during phagocytosis and engulfment. Nat Cell Biol 2:E191-E196.
141. Nobes CD, Hall A. 1999. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 144:1235-1244.
142. Mackay DJ, Hall A. 1998. Rho GTPases. J Biol Chem 273:20685-20688.
143. Jou TS, Leung SM, Fung LM, Ruiz WG, Nelson WJ, Apodaca G. 2000. Selective alterations in biosynthetic and endocytic protein traffic in Madin-Darby canine kidney epithelial cells expressing mutants of the small GTPase Rac1. Mol Biol Cell 11:287-304.
144. Leung SM, Rojas R, Maples C, Flynn C, Ruiz WG, Jou TS, Apodaca G. 1999. Modulation of endocytic traffic in polarized Madin-Darby canine kidney cells by the small GTPase RhoA. Mol Biol Cell 10:4369-4384.
145. Noren NK, Niessen CM, Gumbiner BM, Burridge K. 2001. Cadherin engagement regulates Rho family GTPases. J Biol Chem 276:33305-33308.
146. Kuroda S, Fukata M, Fujii K, Nakamura T, Izawa I, Kaibuchi K. 1997. Regulation of cell-cell adhesion of MDCK cells by Cdc42 and Rac1 small GTPases. Biochem Biophys Res Commun 240:430-435.
147. Takaishi K, Sasaki T, Kotani H, Nishioka H, Takai Y. 1997. Regulation of cell-cell adhesion by rac and rho small G proteins in MDCK cells. J Cell Biol 139:1047-1059.
148. Ridley AJ, Comoglio PM, Hall A. 1995. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol 15:1110-1122.
149. Jou TS, Nelson WJ. 1998. Effects of regulated expression of mutant RhoA and Rac1 small GTPases on the development of epithelial (MDCK) cell polarity. J Cell Biol 142:85-100.
150. Kazmierczak BI, Jou TS, Moslov K, Engel JN. 2001. Rho GTPase activity modulates Pseudomonas aeruginosa internalization by epithelial cells. Cell Microbiol 3:85-98.
151. Kazmierczak BI, Mostov K, Engel JN. 2004. Epithelial cell polarity alters Rho-GTPase responses to Pseudomonas aeruginosa. Mol Biol Cell 15:411-419.
152. Wadia JS, Dowdy SF. 2002. Protein transduction technology. Curr Opin Biotechnol 13:52-56.
153. Wadia JS, Dowdy SF. 2003. Modulation of cellular function by TAT mediated transduction of full length proteins. Curr Protein Pept Sci 4:97-104.
154. Selivanova G, Iotsova V, Okan I, Fritsche M, Strom M, Groner B, Grafstrom RC, Wiman KG. 1997. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 3:632-638.
155. Hupp TR, Sparks A, Lane DP. 1995. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83:237-245.
156. Snyder EL, Meade BR, Saenz CC, Dowdy SF. 2004. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2:E36.
157. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF. 1998. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kipl induces cell migration. Nat Med 4:1449-1452.
158. Gius DR, Ezhevsky SA, Becker-Hapak M, Nagahara H, Wei MC, Dowdy SF. 1999. Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. Cancer Res 59:2577-2580.
159. Ortega S, Malumbres M, Barbacid M. 2002. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602:73-87.
160. Nekhotiaeva N, Elmquist A, Rajarao GK, Hallbrink M, Langel U, Good L. 2004. Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides. FASEB J 18:394-396.
161. Orlando RC. 2002. Mechanisms of epithelial injury and inflammation in gastrointestinal diseases. Rev Gastroenterol Disord 2:S2-S8.
162. Sanders DS. 2005. Mucosal integrity and barrier function in the pathogenesis of early lesions in Crohn's disease. J Clin Pathol 58:568-572.
163. Schmitz H, Barmeyer C, Gitter AH, Wullstein F, Bentzel CJ, Fromm M, Riecken EO, Schulzke JD. 2000. Epithelial barrier and transport function of the colon in ulcerative colitis. Ann N Y Acad Sci 915:312-326.
164. Siccardi D, Turner JR, Mrsny RJ. 2005. Regulation of intestinal epithelial function: A link between opportunities for macromolecular drug delivery and inflammatory bowel disease. Adv Drug Deliv Rev 57:219-235.
165. Coyne CB, Vanhook MK, Gambling TM, Carson JL, Boucher RC, Johnson LG. 2002. Regulation of airway tight junctions by proinflammatory cytokines. Mol Biol Cell 13:3218-3234.
166. Trautmann A, Kruger K, Akdis M, Muller-Wening D, Akkaya A, Brocker EB, Blaser K, Akdis CA. 2005. Apoptosis and loss of adhesion of bronchial epithelial cells in asthma. Int Arch Allergy Immunol 138:142-150.
167. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, Nusrat A. 2003. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol 171:6164-6172.
168. Nusrat A, Parkos CA, Verkade P, Foley CS, Liang TW, Innis-Whitehouse W, Eastburn KK, Madara JL. 2000. Tight junctions are membrane microdomains. J Cell Sci 113:1771-1781.